Evidence map›Paper›PMID 33816221›Full record

ArticleFrontiers in oncology2021

Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report.

Victor C Kok, Chien-Kuan Lee, Yu-Hsin Chiang, Ming-Chih Wang, Yen-Te Lu, Chiu-Chun Cherng, Pei-Yu Lee, Ke-Bin Wang

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Clinicopathologic and molecular characteristics ofTranslational lung cancer research · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Victor C KokDivision of Medical Oncology, KTGH Cancer Center, Kuang Tien General Hospital, Taichung, Taiwan.
Chien-Kuan LeeDepartment of Pathology, Kuang Tien General Hospital, Taichung, Taiwan.
Yu-Hsin ChiangDivision of Chest Surgery, Department of Surgery, Kuang Tien General Hospital, Taichung, Taiwan.
Ming-Chih WangDepartment of Radiation Oncology, Kuang Tien General Hospital, Taichung, Taiwan.
Yen-Te LuDepartment of Radiation Oncology, Kuang Tien General Hospital, Taichung, Taiwan.
Chiu-Chun CherngDivision of Neurosurgery, Department of Surgery, Kuang Tien General Hospital, Taichung, Taiwan.
Pei-Yu LeeDepartment of Diagnostic and Intervention Radiology, Kuang Tien General Hospital, Taichung, Taiwan.
Ke-Bin WangDepartment of Nuclear Medicine, Kuang Tien General Hospital, Taichung, Taiwan.
Kuang Tien General Hospital · TWAsia University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe acquired resistance mechanisms in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer, particularly adenocarcinoma (ADC), following treatment with an EGFR tyrosine kinase inhibitor (TKI) have received extensive investigations. The phenotypic transformation to small cell carcinoma (SCCT) has been estimated to occur in approximately 3 to 10% of patients treated with an EGFR-TKI. The prognosis after SCCT is extremely poor. CASE STUDY: We report about SCCT that occurred 45 months after the initial diagnosis of ADC in an East Asian never-smoker woman with advanced-stage

Indexed as

case reportDel-19 mutationEGFR-mutant lung adenocarcinomasmall cell carcinoma transformationtopotecan (PubChem CID: 60700)

Identifiers

PMID33816221
PMCPMC8012892
OpenAlexW3136422072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.